Medical Stocks: 75% of Americans to Be Obese by 2020

Medical Stocks: 75% of Americans to Be Obese by 2020

Research  these Stocks on Kapitall’s Playground Now

 
research now

America is pretty much eating itself to death. And while there are several directions to point fingers and names to name, we'll leave that to another news blog. (STAY AHEAD OF THE CURVE: Follow Kapitall on Twitter)

As for investing strategy, here are the facts:

The OECD recently predicted that by 2020 75% of the US population will be obese. This implies tens of trillions of dollars in healthcare expenses.

To be clear, obesity is defined according to a body mass index (BMI), which calculates human body fat based on weight and height. A BMI of 30 or greater signifies obesity, while scores between 25 and 30 indicates simply being overweight.

Although America is leading the way in obesity rates, other countries are seeing an increase in obesity too. Zero Hedge reports: "The U.S.'s next closest "competitor" is Mexico with a 30% obesity rate, while Canada and the U.K. have rates of 24% and 23%, respectively. Other highly developed countries such as Germany, Italy and France have rates below 15%, and Japan is all the way down at 3.9%. India’s citizens are the trimmest, with a 2.1% obesity rate. The average for the 34 OECD member countries is 16.9% – exactly half that of the United States."

Health problems associated with obesity are limitless. From clogged arteries, cancer, heart disease, stroke, high blood pressure, to osteoarthritis and gallstones. And the king of all health-concerns: Diabetes, which is also the leading cause of non-traumatic amputations, eye disease, kidney disease, and a major factor in the development of cardiovascular disease. And cardiovascular disease is the number one cause of death in patients with diabetes.

Business Section: Investing Ideas

It's been said that second derivatives of obesity include preventative care plays like Nike (NKE) and Lululemon Athletica (LULU). But we are looking for more pure plays:

Because obesity creates massive profits for the pharma industry, and because American's aren't likely to reverse course on this terrible trend, let's see if we can make our portfolios a little fatter in the process.

We created a universe of healthcare companies with exposure to diabetes, a good starting point for medical exposure.

 

Interactive Chart: Use the Compar-O-Matic to compare analyst ratings for the stocks mentioned below:

 

“1. Abbott Laboratories (ABT, Earnings, Analysts, Financials): Engages in the discovery, development, manufacture, and sale of health care products worldwide. Market cap of $96.13B. Relatively low correlation to the market (beta = 0.31), which may be appealing to risk averse investors. Offers a good dividend, and appears to have good liquidity to back it up–dividend yield at 3.34%, current ratio at 1.54, and quick ratio at 1.32. The stock has gained 26.17% over the last year.

 

“2. Alkermes plc (ALKS, Earnings, Analysts, Financials): Provides extended-release injectable and oral products for the treatment of prevalent and chronic diseases, such as central nervous system disorders, reward disorders, addiction, diabetes, and autoimmune disorders. Market cap of $2.40B. Relatively low correlation to the market (beta = 0.79), which may be appealing to risk averse investors. The stock is a short squeeze candidate, with a short float at 6.31% (equivalent to 5.24 days of average volume). The stock has had a couple of great days, gaining 8.42% over the last week.

 

“3. Alere Inc. (ALR, Earnings, Analysts, Financials): Engages in the development, manufacture, and marketing of consumer and professional medical diagnostic products in the United States and internationally. Market cap of $2.06B. The stock has lost 34.83% over the last year.

 

“4. Amylin Pharmaceuticals, Inc. (AMLN, Earnings, Analysts, Financials): Engages in the discovery, development, and commercialization of drug candidates for the treatment of diabetes, obesity, and other diseases. Market cap of $3.88B. Exhibiting strong upside momentum–currently trading 38.69% above its SMA20, 45.09% above its SMA50, and 93.85% above its SMA200. The stock has had a couple of great days, gaining 56.73% over the last week.

 

“5. Becton, Dickinson and Company (BDX, Earnings, Analysts, Financials): Develops, manufactures, and sells medical devices, instrument systems, and reagents worldwide. Market cap of $16.42B. Relatively low correlation to the market (beta = 0.58), which may be appealing to risk averse investors. The stock has lost 1.41% over the last year.

 

“6. Bristol-Myers Squibb Company (BMY, Earnings, Analysts, Financials): Develops, and delivers innovative medicines that help patients prevail over serious diseases. Market cap of $57.16B. Relatively low correlation to the market (beta = 0.47), which may be appealing to risk averse investors. Offers a good dividend, and appears to have good liquidity to back it up–dividend yield at 4.02%, current ratio at 1.97, and quick ratio at 1.79. The stock has gained 30.82% over the last year.

 

“7. Elan Corporation, plc (ELN, Earnings, Analysts, Financials): Operates as a neuroscience-based biotechnology company primarily in Ireland and the United States. Market cap of $8.73B. The stock has had a good month, gaining 19.03%.

 

“8. Forest Laboratories Inc. (FRX, Earnings, Analysts, Financials): Develops, manufactures, and sells branded and generic forms of ethical drug products. Market cap of $9.23B. Relatively low correlation to the market (beta = 0.68), which may be appealing to risk averse investors. The stock is a short squeeze candidate, with a short float at 7.86% (equivalent to 11.67 days of average volume). The stock has gained 5.75% over the last year.

 

“9. Eli Lilly & Co. (LLY, Earnings, Analysts, Financials): Develops, manufactures, and sells pharmaceutical products worldwide. Market cap of $46.79B. Relatively low correlation to the market (beta = 0.7), which may be appealing to risk averse investors. Offers a good dividend, and appears to have good liquidity to back it up–dividend yield at 4.86%, current ratio at 1.6, and quick ratio at 1.34. The stock has gained 21.34% over the last year.

 

“10. Medtronic, Inc. (MDT, Earnings, Analysts, Financials): Manufactures and sells device-based medical therapies worldwide. Market cap of $40.69B. The stock has gained 1.77% over the last year.

 

“11. Merck & Co. Inc. (MRK, Earnings, Analysts, Financials): Provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. Market cap of $117.86B. Relatively low correlation to the market (beta = 0.65), which may be appealing to risk averse investors. Offers a good dividend, and appears to have good liquidity to back it up–dividend yield at 4.34%, current ratio at 2.04, and quick ratio at 1.66. The stock has gained 21.84% over the last year.

 

“12. Nordisk A/S (NVO, Earnings, Analysts, Financials): Engages in the discovery, development, manufacture, and marketing of pharmaceutical products in Denmark and internationally. Market cap of $101.49B. Relatively low correlation to the market (beta = 0.55), which may be appealing to risk averse investors. Exhibiting strong upside momentum–currently trading 6.57% above its SMA20, 11.26% above its SMA50, and 29.47% above its SMA200. The stock has had a couple of great days, gaining 6.49% over the last week.

 

“13. VIVUS Inc. (VVUS, Earnings, Analysts, Financials): Engages in the development and commercialization of therapeutic products for underserved markets in the United States. Market cap of $2.18B. Exhibiting strong upside momentum–currently trading 6.17% above its SMA20, 29.6% above its SMA50, and 103.1% above its SMA200. The stock has had a couple of great days, gaining 6.59% over the last week.

 

 

(Written by Rebecca Lipman. Data sourced from Finviz.)

 

Use Kapitall's Tools: Looking for ways to analyze this list?

Use this article snapshot as a launch pad (click here for help): Simply click on the links, and use Kapitall's tab navigation to browse through the data…

 

Analyze These Ideas: Getting Started

Dig Deeper: Access Company Snapshots, Charts, Filings

New to Kapitall?

1. New to the site? Click here to register for a free account, and gain access to more tools and data
2. Looking for more investing ideas like this? Click here to sign up for your free copy of Kapitall Weekly
3. Follow us on SeekingAlpha, Motley Fool, Nasdaq and Twitter

 

 

 

playfor100kwirebanner2png

3 Responses to “Medical Stocks: 75% of Americans to Be Obese by 2020”

  1. Christopher says:

    Health problems associated with obesity are limitless. Obesity can lead a lot of disease such as clogged arteries, cancer, heart disease, stroke, high blood pressure, osteoarthritis and gallstones. Obesity can be reduced by maintaining proper diet.
    health news

  2. Aspca says:

    I am happy with your structure

  3. I recommend to do sport and be very healthy.

Leave a Reply

Protected by WP Anti Spam

wirebannerscompetepng